<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1485</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>9811690</PubmedId>
            <Abstract>We have evaluated the potential of conferring protective immunity to herpes simplex virus type 2 (HSV-2) by selectively inducing an HSV-specific CD8(+) cytotoxic T-lymphocyte (CTL) response directed against a single major histocompatibility complex class I-restricted CTL recognition epitope. We generated a recombinant vaccinia virus (rVV-ES-gB498-505) which expresses the H-2Kb-restricted, HSV-1/2-cross-reactive CTL recognition epitope, HSV glycoprotein B residues 498 to 505 (SSIEFARL) (gB498-505), fused to the adenovirus type 5 E3/19K endoplasmic reticulum insertion sequence (ES). Mucosal immunization of C57BL/6 mice with this recombinant vaccinia virus induced both a primary CTL response in the draining lymph nodes and a splenic memory CTL response directed against HSV gB498-505. To determine the ability of the gB498-505-specific memory CTL response to provide protection from HSV infection, immunized mice were challenged with a lethal dose of HSV-2 strain 186 by the intranasal (i.n.) route. Development of the gB498-505-specific CTL response conferred resistance in 60 to 75% of mice challenged with a lethal dose of HSV-2 and significantly reduced the levels of infectious virus in the brains and trigeminal ganglia of challenged mice. Finally, i.n. immunization of C57BL/6 mice with either a recombinant influenza virus or a recombinant vaccinia virus expressing HSV gB498-505 without the ES was also demonstrated to induce an HSV-specific CTL response and provide protection from HSV infection. This finding confirms that the induction of an HSV-specific CTL response directed against a single epitope is sufficient for conferring protective immunity to HSV. Our findings support the role of CD8(+) T cells in the control of HSV infection of the central nervous system and suggest the potential importance of eliciting HSV-specific mucosal CD8(+) CTL in HSV vaccine design.</Abstract>
            <ArticleYear>1998</ArticleYear>
            <ArticlePages>9567-74</ArticlePages>
            <ArticleTitle>Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Blaney</LastName>
                    <ForeName>J E</ForeName>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author>
                    <LastName>Nobusawa</LastName>
                    <ForeName>E</ForeName>
                </Author>
                <Author>
                    <LastName>Brehm</LastName>
                    <ForeName>M A</ForeName>
                </Author>
                <Author>
                    <LastName>Bonneau</LastName>
                    <ForeName>R H</ForeName>
                </Author>
                <Author>
                    <LastName>Mylin</LastName>
                    <ForeName>L M</ForeName>
                </Author>
                <Author>
                    <LastName>Fu</LastName>
                    <ForeName>T M</ForeName>
                </Author>
                <Author>
                    <LastName>Kawaoka</LastName>
                    <ForeName>Y</ForeName>
                </Author>
                <Author>
                    <LastName>Tevethia</LastName>
                    <ForeName>S S</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.</Affiliations>
            <ArticleChemicalList>Antigens, Viral;Epitopes;H-2 Antigens;H-2Kb protein, mouse;Histocompatibility Antigens Class I;Viral Envelope Proteins;glycoprotein B, herpes simplex virus type 2</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antigens, Viral(genetics); Central Nervous System(immunology; virology); Epitopes(genetics); H-2 Antigens; Herpes Genitalis(immunology; prevention &amp; control; virology); Herpesvirus 2, Human(genetics; immunology; isolation &amp; purification); Histocompatibility Antigens Class I; Immunity, Mucosal; Immunization; Immunologic Memory; Male; Mice; Mice, Inbred C57BL; Recombination, Genetic; T-Lymphocytes, Cytotoxic(immunology); Vaccinia virus(genetics); Viral Envelope Proteins(genetics; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>72</Volume>
                <Issue>12</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>gB498-505</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SSIEFARL</LinearSequence>
                        <StartingPosition>498</StartingPosition>
                        <EndingPosition>505</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>VGBEK1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10298</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>61086</EpitopeId>
                <ReferenceStartingPosition>498</ReferenceStartingPosition>
                <ReferenceEndingPosition>505</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Exact match to reference information</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope was originally identified for HSV-1. The SSIEFARL epitope is identical in both HSV-1 (gB498-505) and HSV-2 (gB496-503).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>24506</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SSIEFARL</LinearSequence>
                                            <StartingPosition>498</StartingPosition>
                                            <EndingPosition>505</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>VGBEK1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10298</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>gB498-505</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11320</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Other</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10298</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Mice were immunized with a recombinant influenza virus expressing the gB498-505 epitope within the flu NA stalk protein.  Splenocytes or lymph node cells from immunized mice were either restimulated in vitro with HSV-infected B6/WT-3 cells or incubated with no added stimulator cells for 5 days. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Unknown/Unspecified</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000067</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>gB498-505</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SSIEFARL</LinearSequence>
                                        <StartingPosition>498</StartingPosition>
                                        <EndingPosition>505</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>VGBEK1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10298</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>13</NumberOfSubjectsTested>
                            <AssayComments>Positive CTL responses to the epitope were seen in the draining lymph nodes as well as in the spleen at 5 days post-immunization (8 mice). Memory CTL responses were positive at 4 weeks post immunization (5 mice).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>24502</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SSIEFARL</LinearSequence>
                                            <StartingPosition>498</StartingPosition>
                                            <EndingPosition>505</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>VGBEK1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10298</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>gB498-505</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with a recombinant vaccinia virus encoding the gB498-505 epitope fused to an endoplasmic reticulum insertion sequence. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymph node cells</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Fibroblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000067</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>gB498-505</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SSIEFARL</LinearSequence>
                                        <StartingPosition>498</StartingPosition>
                                        <EndingPosition>505</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>VGBEK1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10298</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>CTL responses to epitope were analyzed in the hilar and submaxillary lymph nodes at 8 days post-immunization. CTL responses to the epitope were also analyzed in the spleen 6 weeks post-immunization to assess the memory response. The frequency of memory CTL was determined by a limiting dilution assay.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <TCellId>24507</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SSIEFARL</LinearSequence>
                                            <StartingPosition>498</StartingPosition>
                                            <EndingPosition>505</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>VGBEK1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10298</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>gB498-505</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11320</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Fibroblast</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10298</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Mice were immunized with a recombinant influenza virus expressing the gB498-505 epitope within the flu NA stalk protein.  Splenocytes or lymph node cells from immunized mice were either restimulated in vitro with HSV-infected, mitomycin C treated B6/WT-3 cells or incubated with no added stimulator cells for 5 days. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Unknown/Unspecified</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <SourceOrganismId>10000067</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Human herpesvirus 1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10298</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>13</NumberOfSubjectsTested>
                            <AssayComments>Positive CTL responses to the epitope were seen in the draining lymph nodes as well as in the spleen at 5 days post-immunization (8 mice). Memory CTL responses were positive at 4 weeks post immunization (5 mice).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>gB498-505</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SSIEFARL</LinearSequence>
                        <StartingPosition>496</StartingPosition>
                        <EndingPosition>503</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAB72100.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10310</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>61086</EpitopeId>
                <ReferenceStartingPosition>496</ReferenceStartingPosition>
                <ReferenceEndingPosition>503</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope was originally identified for HSV-1. The SSIEFARL epitope is identical in both HSV-1 (gB498-505) and HSV-2 (gB496-503).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>1463064</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SSIEFARL</LinearSequence>
                                            <StartingPosition>496</StartingPosition>
                                            <EndingPosition>503</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAB72100.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10310</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>gB498-505</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with recombinant vaccinia virus encoding the gB498-505 epitope alone or the gB498-505 epitope fused to an endoplasmic reticulum insertion sequence. .</ImmunizationComments>
                        </Immunization>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Human herpesvirus 2</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10310</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>127</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>56</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>29</NumberOfSubjectsResponded>
                            <ResponseFrequency>51.8</ResponseFrequency>
                            <AssayComments>Mice were immunized with recombinant vaccinia virus encoding the gB498-505 epitope. Four to six weeks later, mice were challenged intranasally with a lethal dose of HSV-2 186 and monitored for lethality. Viral titers were also assessed 5 days later in the brains and trigeminal ganglia of immunized and unimmunized mice (Figure 4). Immunized mice survived longer and had lower viral titres in the CNS.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 7</LocationOfData>
                        <TCellId>1463068</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SSIEFARL</LinearSequence>
                                            <StartingPosition>496</StartingPosition>
                                            <EndingPosition>503</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAB72100.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10310</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>gB498-505</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11320</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with recombinant influenza virus expressing the gB498-505 epitope within the flu NA stalk protein. .</ImmunizationComments>
                        </Immunization>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Human herpesvirus 2</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10310</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>127</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>8</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>62.5</ResponseFrequency>
                            <AssayComments>Mice were immunized with recombinant influenza virus expressing the gB498-505 epitope within the flu NA stalk protein. Four weeks after immunization, mice were challenged intranasally with a lethal dose of HSV-2 186 and monitored for lethality.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

